H. pylori - Ace Infectious
Analysis of H. pylori Drugs
Services
Online Inquiry

Analysis of H. pylori Drugs

The safety and efficacy of a drug are key focuses of drug development. During the drug development process and production process, a number of analyses are required to determine the safety and efficacy of a drug. Of these, the most important is the analysis of drug quality and safety. Additionally, there are more detailed analyses, such as ADME testing. Ace Infectious provides comprehensive analytical services for H. pylori drugs, including general testing, DMPK studies, drug resistance assessment, and anti-drug antibody testing. Our comprehensive drug analysis services better support the development of H. pylori small molecule drugs, therapeutic peptide and protein drugs, and polysaccharide drugs.

Fig. 1 Analysis of H. pylori drugs - Ace Infectious

General testing of H. pylori drugs

We provide general testing for H. pylori drugs, including quality testing, toxicity testing, and stability testing. This service is for the safety evaluation and quality assessment of H. pylori drugs after they are put into production. In addition, this service can also provide quality identification and safety assessment for H. pylori drugs under development. Among them, H. pylori drug quality identification service is our competitive service. We have advanced structural analysis equipment to analyze H. pylori small molecule drugs, therapeutic peptides and proteins, and polysaccharide drugs. For drug identification of H. pylori as a drug target, we can provide highly purified target proteins to detect drug-target interactions.

DMPK studies of H. pylori drugs

We provide trustworthy in silico, in vitro, and in vivo drug metabolism and pharmacokinetics (DMPK) consulting and testing services to facilitate the development of H. pylori drugs. This service is designed to analyze and evaluate drug molecules during the hit-to-lead and lead optimization phases of the H. pylori drug development process. In combination with toxicity testing, we can assist with the hit-to-lead and lead optimization phases of H. pylori small molecule drug development. The biggest advantage of our DMPK studies is fast articulation. Once the drug to be tested is synthesized, we perform timely assays. In addition, our experimental data is uploaded to the cloud in a timely manner to facilitate analysis of the results and make development recommendations.

Drug resistance assessment and anti-drug antibody testing

The rate of mutation and homologous recombination in H. pylori is high. Genetic mutations are one of the important factors of drug resistance in H. pylori. We provide drug resistance assessment to detect the effect of newly developed drugs on drug-resistant H. pylori and to detect the resistance rate of H. pylori after being subjected to multiple and prolonged effects of newly developed drugs.

H. pylori therapeutic peptides and proteins that may cause anti-drug antibodies (ADA) in humans and result in reduced efficacy or other side effects. We offer rodent-based preclinical ADA testing for the evaluation of H. pylori therapeutic peptides and proteins. Our ADA testing services can also be combined with PK analysis to fully analyze therapeutic peptides and proteins.

Ace Infectious also provides additional H. pylori drug analysis services, including immunogenicity testing, pharmacological economy assessment, and comparative evaluation.

Cooperate with us

Ace Infectious provides a one-stop shop for H. pylori drugs. We provide analytical services for H. pylori drugs to meet the needs of both the development process and the manufacturing process of H. pylori drugs. Please contact us for comprehensive H. pylori drug analysis services.

※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.